At a glance
- Originator GlaxoSmithKline
- Class Acyclic acids; Antihyperlipidaemics; Phenylurea compounds
- Mechanism of Action Peroxisome proliferator-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
- 03 Nov 1999 New profile
- 03 Nov 1999 Preclinical development for Hyperlipidaemia in USA (Unknown route)